Policy Prescription
FEBRUARY 9, 2022
Mark Cuban’s new online pharmacy venture – the Mark Cuban Cost Plus Drug Company (“Cost Plus Drug”) – will not help overcome the biggest obstacle to drug affordability in America, which is drug company monopolies on patented brand name prescription drugs. That’s even cheaper than foreign online pharmacy prices , including in India. .
Drug Discovery World
JANUARY 17, 2023
Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition. . Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Perficient: Drug Development
FEBRUARY 20, 2024
Among these, pharmacy benefit managers (PBMs) play a crucial role, handling reimbursements and negotiations with drug manufacturers and pharmacies. This ongoing struggle contributes to the broader atmosphere of tension within the pharmaceutical sector. Prescription drugs reach patients through a complex web of entities.
The Pharma Data
SEPTEMBER 21, 2020
Acella Pharmaceuticals is recalling two types of its thyroid medication as the drugs may be too weak to properly treat those who take them. . Photo by Adam from UK. This follows a similar recall of thyroid medications that was issued by the FDA in recent weeks.
The Pharma Data
DECEMBER 17, 2020
With years of pharmaceutical expertise to her credit, Dr. Johnson first garnered inspiration for her professional future during her formative years. Doctor Johnson has had an inspiring career that encompasses several aspects of the pharmacy industry. Dr. Johnson assists in interpreting the results when they become available.
Drug Target Review
DECEMBER 22, 2023
The regulatory science project I pursued for my first master’s degree titled, “21st Century Pharmaceutical Excipients: Consequences of a Global Supply Chain and Lack of Excipient Regulations” aimed to draw attention to the risks created by the lack of sufficient oversight of the pharmaceutical excipient supply chain.
Alta Sciences
OCTOBER 30, 2023
In this in-depth discussion on the FDA’s June draft guidance on clinical investigation of psychedelic drugs, Doctors Denise Milovan, Debra Kelsh, and Beatrice Setnik share insights into the potential need for additional methodological adaptations for study designs, in order to evaluate the safety and effects. Listen here.
Expert insights. Personalized for you.
52 
Let's personalize your content